摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

catharanthine | 1212401-29-0

中文名称
——
中文别名
——
英文名称
catharanthine
英文别名
3,4-didehydro-ibogamine-18-carboxylic acid methyl ester;(+/-)-Catharanthin;Catharanthin;Catharanthine hcl;methyl 17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8,16-pentaene-1-carboxylate
catharanthine化学式
CAS
1212401-29-0
化学式
C21H24N2O2
mdl
——
分子量
336.434
InChiKey
CMKFQVZJOWHHDV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    491.5±45.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    45.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    catharanthine 生成 ent-2',2'-dimethyl-3,4-didehydro-[1,3]oxazino[3',4',5':16,17,18]ibogamine
    参考文献:
    名称:
    Cataranthine的结构,这是iboga生物碱的新型变体
    摘要:
    DOI:
    10.1016/s0040-4039(01)99232-9
  • 作为产物:
    描述:
    参考文献:
    名称:
    Studies in biomimetic alkaloid syntheses. 14. Controlled, selective syntheses of catharanthine and tabersonine, and related desethyl compounds, through generation of 15-oxosecodine intermediates
    摘要:
    DOI:
    10.1021/jo00365a012
点击查看最新优质反应信息

文献信息

  • Ceric ammonium nitrate-promoted oxidative coupling reaction for the synthesis and evaluation of a series of anti-tumor amide anhydrovinblastine analogs
    作者:Weibin Song、Min Lei、Kun Zhao、Lingjun Hu、Yuhui Meng、Dean Guo、Xuan Liu、Lihong Hu
    DOI:10.1016/j.bmcl.2011.10.114
    日期:2012.1
    of ceric ammonium nitrate (CAN) was developed. Under the optimized reaction conditions, we synthesized a new series of amide anhydrovinblastine analogs substituted at the vindoline moiety of C-23 site and, evaluated for their proliferation inhibition against HeLa cell. The aryl-substituted derivatives showed loss of potency, while alkyl-substituted derivatives retained some of its cytotoxic potency
    开发了一种新的,实用,有效的方法,在硝酸铈铵(CAN)存在下,通过长春花碱与长春胺碱的氧化偶联反应来合成脱水长春碱AVBL(1f)。在优化的反应条件下,我们合成了一系列在C-23位点的长春藤碱部分取代的酰胺类脱水长春碱类似物,并评估了其对HeLa细胞的增殖抑制作用。芳基取代的衍生物显示出效力丧失,而烷基取代的衍生物保留了其部分细胞毒性效力。所述异-butylamide化合物10B和2- furancorboxamide化合物18B相比,阳性对照AVBL显示了类似的细胞毒性效力。
  • Studies in plant tissue culture
    作者:James P. Kutney、Barbara Aweryn、Lewis S.L. Choi、Toshio Honda、Pawel Kolodziejczyk、Norman G. Lewis、Toshitsugu Sato、Stephen K. Sleigh、Kenneth L. Stuart、Brian R. Worth、Wolfgang G.W. Kurz、Kenneth B. Chatson、Friedrich Constabel
    DOI:10.1016/s0040-4020(01)88620-8
    日期:1983.1
    Studies involving plant tissue cultures of Catharanthus roseus are described. Investigations concerning the propagation of cell lines of this plant for the purposes of producing indole alkaloids within the Corynanthé, Aspidosperma and Iboga families are presented. The utilization of such tissue culture systems for studies in biosyntheses and isolation of enzymes are also discussed.
    描述了涉及长春花的植物组织培养的研究。进行了有关该植物细胞系繁殖的研究,目的是在Corynanthé,Aspidosperma和Iboga家族中生产吲哚生物碱。还讨论了这种组织培养系统在生物合成和酶分离研究中的应用。
  • [EN] COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS RELATIFS À DES SELS DE MÉDIATEURS SPÉCIALISÉS DE PRO-RÉSOLUTION D'INFLAMMATION
    申请人:THETIS PHARMACEUTICALS LLC
    公开号:WO2017210604A1
    公开(公告)日:2017-12-07
    The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
    本发明涉及公式I-IV的化合物,它们是炎症特殊脂质介质的盐,包括含有它们的组合物,并且在治疗由慢性或过度炎症或两者都特征的各种疾病和障碍中使用它们的方法。
  • ANTI-CANCER PHOSPHONATE ANALOGS
    申请人:Boojamra Constantine G.
    公开号:US20100022467A1
    公开(公告)日:2010-01-28
    The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    本发明涉及磷取代的抗癌化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法,还涉及用于制备这些化合物的过程和中间体。
  • 10'-FLUORINATED VINCA ALKALOIDS PROVIDE ENHANCED BIOLOGICAL ACTIVITY AGAINST MDR CANCER CELLS
    申请人:Boger Dale L.
    公开号:US20120329822A1
    公开(公告)日:2012-12-27
    A 10′-fluoro-vinca alkaloid compound or its pharmaceutically acceptable salt is disclosed, as are methods of its preparation and use. A disclosed 10′-fluoro-vinca alkaloid compound has better cytotoxic potency against leukemia and cancer cell lines, and is about 8-times more cytotoxic to a multiple drug resistant cancer cell line than is a parental 10′-unsubstituted vinca alkaloid.
    本发明揭示了10'-氟-长春碱化合物或其药学上可接受的盐,以及其制备和使用的方法。所揭示的10'-氟-长春碱化合物对白血病和癌细胞系具有更好的细胞毒性,对多药耐药癌细胞系的细胞毒性约为亲代10'-未取代长春碱的8倍。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

马山茶碱 非洲伏康树碱 长春质碱 老刺木任 硫酸长春质碱 海尼山辣椒碱羟基假吲哚 榴花碱 柳黄酸 伏康京碱 伊菠胺-18-羧酸甲酯 伊菠胺 伊菠加因盐酸盐 伊博格碱 7-羟基-1-去氢老刺木碱 20-羟基榴花碱 14-((3alpha)-17-甲氧基-17-氧代派利文碱-3-基)-伊菠胺-18-羧酸甲酯 13-甲氧基-14-[(3A)-17-甲氧基-17-氧代派利文碱-3-基]-伊菠胺-18-羧酸甲酯 13-甲氧基-12-[(3a)-17-甲氧基-17-氧代派利文碱-3-基]-伊菠胺-18-羧酸甲酯 12-((3alpha)-17-甲氧基-17-氧代派利文碱-3-基)-伊菠胺-18-羧酸甲酯 11-羟基狗牙花定 10-羟基狗牙花定 (4a,20S)-20-羟基伊菠胺-18-羧酸甲酯 (2S)-1,2,3,4,4abeta,5,6,7,7a,12bbeta-十氢-4alpha-(1-羟基乙基)-9-甲氧基-2alpha,5alpha-甲桥吲哚并[3,2-d][1]苯并氮杂卓-7alpha-醇 epiibogaine N-methylcatharanthine quaternary salt lauryl albifloranine (+/-)-Coronaridine 18-methoxycoronaridine hydrochloride voacangine 19-Ethoxycoronaridin N-methylibogaine 2-(dimethylamino)ethyl (1R,15R,17S,18S)-17-ethyl-7-hydroxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene-3-carboxylate ethyl (1R,15R,17S,18S)-17-ethyl-7-hydroxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene-3-carboxylate [(1R,15R,17S,18S)-3-dimethoxyphosphoryl-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraen-7-yl] 4-methylpiperazine-1-carboxylate hydron;methyl (1S,15R,17S,18S)-17-ethyl-14-hydroxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate;chloride eglandine Ibogamine-18-carboxylic acid, 19-hydroxy-12-methoxy-, methyl ester, (19R)- 3-(beta-Hydroxyethyl)coronaridine Ibogamine-18-carboxylic acid, 13,20-dihydroxy-, methyl ester, (4alpha,20S)- 10-Hydroxyheyneanine Ibogamine-18-carboxylic acid, 21-hydroxy-, methyl ester Ibogamin-20-ol, 8,19-epoxy-12-methoxy-, (4alpha,8beta,19S,20S)- Voacangine Conopharyngine ibogaline (+/-)-coronaridine (-)-Ibogaine (15S,17R)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene (15S,17R)-17-ethyl-7-methoxy-3-methyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Voacangine 11-(3,4-dimethoxybenzyl)